Early Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT07185932 Sponsor: Shanghai Changzheng Hospital Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Early Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT07185932
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form agreeing to take part
  • You are between 18 and 75 years old (any gender)
  • You have been diagnosed with fatty liver disease within the last 6 months
  • You have at least one of the following: you are overweight or obese (BMI of 23 or above); you have type 2 diabetes; or you have at least two signs of metabolic problems, such as a large waist size, high blood pressure, high triglycerides (a type of fat in the blood), low "good" cholesterol (HDL), blood sugar levels in the pre-diabetes range, signs of insulin resistance, or raised levels of a marker of inflammation in the blood (confirm with trial site)
  • A special type of MRI scan has shown that at least 8% of your liver is made up of fat

Who may not be able to join:

  • You have cirrhosis (severe scarring of the liver), confirmed by tests or biopsy
  • You have another type of long-term liver disease, such as viral hepatitis, autoimmune hepatitis, alcoholic liver disease, or liver damage from medication
  • Your fatty liver is caused by something else, such as a medication, nutritional treatment through a drip, or an underactive thyroid
  • You have taken gut bacteria-altering supplements or probiotics, or have recently changed certain medications (such as liver, diabetes, or cholesterol drugs) within the last 4 weeks
  • You have taken certain specific medications that can affect fatty liver disease within the last 12 weeks, unless you have been on a stable dose for at least 24 weeks (confirm with trial site)
  • Your diabetes is poorly controlled, with an HbA1c (a measure of blood sugar over time) above 9%
  • You have yellowing of the skin or eyes (jaundice) or reduced kidney function, based on blood test results
  • You have previously had weight-loss (bariatric) surgery
  • You have, or are suspected to have, cancer
  • You have a serious ongoing health condition, such as certain inflammatory diseases, bile or pancreas problems, a current infection, severe heart, lung, or blood disease, a heart attack or stroke in the last 6 months, or a significant mental health condition
  • You have HIV
  • You have a known allergy to a medication called rifaximin
  • You are unable to have an MRI scan — for example, because you have certain metal implants, experience severe claustrophobia, or your body size is larger than the scanner can accommodate
  • You are pregnant, breastfeeding, or planning to become pregnant
  • You have taken part in another medication trial within the last 3 months
  • The trial doctors have another reason they feel makes it unsuitable for you to join (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: +8613482705212

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Shanghai Changzheng Hospital
Registry
ClinicalTrials.gov
Start date
10 August 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The change in liver fat content measured by MRI at 24 weeks of treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov